Promonitor

2,900 views
2,651 views

Published on

Alternativa para el tratamiento de enfermedades inflamatorias crónicas.

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,900
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
55
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • Resultados solo aplicables a pacientes de reumatología
  • Resultados solo aplicables a pacientes de reumatología
  • Promonitor

    1. 1. MONITORING BIOLOGICALS
    2. 2. Biological drugs <ul><li>A great alternative for the treatment of chronic inflammatory diseases (rheumatology and gastroenterology). </li></ul><ul><li>Most common drugs used: </li></ul><ul><ul><ul><ul><ul><li>Infliximab (Remicade ® ) </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Adalimumab (Humira ® ) </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Etanercept (Enbrel ® ) </li></ul></ul></ul></ul></ul><ul><li>Structural differences with different immunogenicity grades </li></ul>+ Immunogenicity -
    3. 3. Immunogenicity and bioavailability <ul><li>The development of antibodies against biologicals leads to a lack of efficiency of the therapy. </li></ul><ul><li>Low levels of biologicals in serum is correlated to a lack of efficiency of the drug** </li></ul>*“Guidelines on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins of 31 July 2007” **Clinical validation with 1400 samples of 70 RA patients “ All therapeutic proteins are potentially immunogenic”* Time after beginning treatment (weeks) Free Infliximab (ug/ml) 10xanti-Infliximab (UA/ml) DAS28
    4. 4. References… “ Several studies have shown that immunogenicity is associated with allergic reactions and loss of response in a significant number of patients treated with chimeric or human therapeutic antibodies. Monitoring of drug levels as well as of antibodies against therapeutic antibodies may lead to more rational treatment strategies.” Wolbink et al. Curr Op Rheum 2009. “ Secondary response failure is associated with low trough levels of anti-TNF-alpha biologicals and development of antibodies against these drugs. Indeed, trough level assessments of anti-TNF-alpha drugs and measurements of antibodies against these biologicals are among the parameters that best predict the response of individual RA patients” Radstake et al. Ann.Rheum.Dis 2009 “ Assesments of bioavailability and immunogenicity of infliximab may be used to optimize dose regimens and prevent prolonged use of inadequate therapy .” Svenson et al. Rheum 2007. “ We show that determining the immunogenic status of a non responding patient may be important for further decision making and could assist in developing an optimised treatment for the individual patient.” Bartelds et al. Ann.Rheum.Dis 2009
    5. 5. Nowadays… <ul><li>Clinicians monitor patients under biological treatment based on subjective or unspecific parameters: </li></ul><ul><ul><ul><li>DAS28 (disease activity score): measurement of swollen and tender joints </li></ul></ul></ul><ul><ul><ul><li>HAQ (health assessment questionnaire): functional capability questionnaire </li></ul></ul></ul><ul><ul><ul><li>Intensity of pain: based on a scale from 0 to 10 </li></ul></ul></ul><ul><ul><ul><li>Unspecific analytical markers: RCP, RF, ESR </li></ul></ul></ul>Monitoring biological drugs is a regulatory requirement , to increase uniformity and consistency of measurement methods of patient´s response
    6. 6. <ul><li>Double test to determine: </li></ul><ul><ul><ul><ul><ul><li>Serum levels of biological. </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Antibodies against drugs. </li></ul></ul></ul></ul></ul><ul><li>Therapeutic parameterization of biological treatment. </li></ul><ul><li>Early prediction of infusion reactions. </li></ul><ul><li>Accurately predicts patient´s response to treatment. </li></ul><ul><li>Optimizes treatment, assuring the correct therapy. </li></ul><ul><li>Cost-effective of biological therapies. </li></ul>PROMONITOR “ Early prediction of treatment failure”
    7. 7. Results of the clinical validation >1.5  g/ml <15 UA/ml <ul><ul><li>* Clinical validation with 1400 samples of 70 RA patients </li></ul></ul>
    8. 8. PROMONITOR <ul><li>Interpretation guidelines in RA, based on the clinical validation performed in Proteomika* </li></ul>* Clinical validation with 1400 samples of 70 RA patients Analysis of infliximab and antibodies against infliximab IFX > 1.5 ug/ml and Antibodies negative IFX < 1.5 ug/ml and Antibodies positive Good clinical response Bad responders Adequate treatment Treatment maybe is not efficient. Surveillance and monitoring required.
    9. 9. Results of the clinical validation <ul><ul><li>*Clinical study with samples from Hospital universitario La Paz </li></ul></ul>< 0.8 ug/ml < 8 AU/ml
    10. 10. PROMONITOR <ul><li>Interpretation guidelines for Adalimumab in RA, based on the clinical validation performed in Proteomika* </li></ul>* Clinical validation with 180 samples of RA patients Analisys of adalimumab and antibodies against adalimumab ADA > 0.8 ug/ml and Antibodies negative ADA < 0.8 ug/ml and Antibodies positive Good clinical response Bad responder Adequate treatment Treatment maybe is not efficient. Surveillance and monitoring required.
    11. 11. PROMONITOR PROMONITOR Optimizes each patient´s therapy Adequate drug level+ no antibody response Decreased drug level + antibody response Low drug level+ significant antibody production Treatment OK Consider increasing dosage or frequency of dosage Consider switching to another drug
    12. 12. PROMONITOR <ul><li>ELISA immunoassay in serum samples, easily reproducible with high specificity and sensitivity . </li></ul><ul><li>Extended menu for a wide variety of biologicals : </li></ul><ul><ul><ul><ul><li>Infliximab (Remicade ® ) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Adalimumab (Humira ® ) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Etanercept (Enbrel ® )* </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Rituximab (MabThera ® )* </li></ul></ul></ul></ul><ul><li>Sample volume required: 40µl of serum for each assay. </li></ul><ul><li>Sample extraction must be immediately before drug administration. </li></ul><ul><ul><li>*Launch 2010 </li></ul></ul>
    13. 13. PROMONITOR ELISA KIT <ul><li>48 test (24 immunogenicity assays and 24 bioavailability assays) </li></ul><ul><li>4 batches of 6 samples can be performed </li></ul><ul><li>Sample type: serum </li></ul><ul><li>Volume required: 40µl each assay. </li></ul><ul><li>High specificity (100%) and sensitivity (>90%) </li></ul><ul><li>Total assay time: 6h </li></ul><ul><li>Hands-on-time: 1.5h </li></ul>PROMONITOR KIT Cat. No. Promonitor IFX PG-PIFX-10200 Promonitor ADA PG-PADA-10700
    14. 14. MARKET <ul><li>Patients undergoing these biological therapies are affected by chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. </li></ul><ul><li>¹ WHO. Disease and injury regional estimates for 2004 </li></ul><ul><li>² Loftus EV Jr . Clinical epidemiology of inflammatory bowel disease : Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17. </li></ul><ul><li>20% of the total affected population are treated with biological drugs . </li></ul>Pathology Prevalence Europe Rheumatoid Arthritis 0.5-1 % 6.200.000 ¹ Inflammatory Bowel Disease 0.3 % 2.200.000 ² TOTAL 8.400.000 20%TOTAL 1.680.000

    ×